Drug resistance in metastatic castration-resistant prostate cancer (Q34139362)

31 July 2017

Drug resistance in metastatic castration-resistant prostate cancer (English)

1 reference

31 July 2017

1 reference

Alberto Ocana

2

0 references

Ian F. Tannock

series ordinal

3

object named as

Ian F Tannock

1 reference

31 July 2017

1

Bostjan Seruga

1 reference

PubMed ID

20859283

31 July 2017

language of work or name

English

0 references

publication date

21 September 2010

1 reference

Nature Reviews Clinical Oncology

31 July 2017

1 reference

31 July 2017

8

1 reference

31 July 2017

1

1 reference

31 July 2017

12-23

1 reference

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

31 July 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Cancer treatment-induced bone loss in breast and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Drug resistance and the solid tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Targeting the cancer kinome through polypharmacology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Early androgen deprivation for prostate cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Androgen receptor and growth factor signaling cross-talk in prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

The development of androgen-independent prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Molecular biology of the androgen receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Integrative molecular concept modeling of prostate cancer progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Molecular determinants of resistance to antiandrogen therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

The role of androgen receptor mutations in prostate cancer progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

The role of MAPK pathways in the action of chemotherapeutic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Survivin mediates resistance to antiandrogen therapy in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Bcl-xL Mediates a Survival Mechanism Independent of the Phosphoinositide 3-Kinase/Akt Pathway in Prostate Cancer Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Integrins in cancer: biological implications and therapeutic opportunities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Exploiting tumour hypoxia in cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

High interstitial fluid pressure - an obstacle in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Exploring the origins of the normal prostate and prostate cancer stem cell

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Prostate cancer stem cells: a new target for therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Neuroendocrine differentiation in the progression of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Environment-mediated drug resistance: a major contributor to minimal residual disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Acquired multicellular-mediated resistance to alkylating agents in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Understanding the biology of bone metastases: key to the effective treatment of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Osteoblasts in prostate cancer metastasis to bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

The role of Src in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Microtubules and resistance to tubulin-binding agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Multidrug resistance in cancer: role of ATP-dependent transporters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Do beta-tubulin mutations have a role in resistance to chemotherapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Microtubule-targeted anticancer agents and apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Bone marrow aspiration for disseminated tumor cell detection: a must-have test or is the jury still out?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Steroid hormone receptors in prostate cancer: a hard habit to break?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Genomic strategy for targeting therapy in castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Epothilones: tubulin polymerization as a novel target for prostate cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.136

Second-line chemotherapy for advanced hormone-refractory prostate cancer

31 March 2020

1 reference

12 December 2020

CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity

1 reference

12 December 2020

Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

1 reference

12 December 2020

Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer

1 reference

12 December 2020

Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.

1 reference

12 December 2020

Bcl2 is the guardian of microtubule integrity

1 reference

12 December 2020

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group

1 reference

12 December 2020

10.1038/NRCLINONC.2010.136

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

20859283